

Oncolytic Viruses and Their Application to Cancer Imm

Cancer Immunology Research

2, 295-300

DOI: [10.1158/2326-6066.cir-14-0015](https://doi.org/10.1158/2326-6066.cir-14-0015)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. <i>Cancer Gene Therapy</i> , 2014, 21, 261-263.	2.2	22
2	Cellular Factors Promoting Resistance to Effective Treatment of Glioma with Oncolytic Myxoma Virus. <i>Cancer Research</i> , 2014, 74, 7260-7273.	0.4	26
3	Oncolytic Viruses and Their Application to Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 295-300.	1.6	308
4	Correction: Oncolytic Viruses and Their Application to Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 699-699.	1.6	1
5	Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly". <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15018.	2.0	11
6	Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. <i>Oncolytic Virotherapy</i> , 2015, 4, 183.	6.0	16
7	A cross-talk network that facilitates tumor virotherapy. <i>Nature Medicine</i> , 2015, 21, 426-427.	15.2	1
9	Arming oncolytic viruses to leverage antitumor immunity. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 959-971.	1.4	53
10	Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8 + T-cell Activation Against Tumors. <i>Molecular Therapy</i> , 2015, 23, 1092-1102.	3.7	6
11	Releasing the Brake on Oncolytic Viral Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 5417-5419.	3.2	3
12	MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. <i>Journal of Virology</i> , 2015, 89, 10637-10647.	1.5	30
13	Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 2812-2814.	0.8	36
14	Role of NK cells in immunotherapy and virotherapy of solid tumors. <i>Immunotherapy</i> , 2015, 7, 861-882.	1.0	17
15	TGF β 2 Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. <i>Cancer Research</i> , 2015, 75, 5273-5282.	0.4	75
16	Oncolytic viruses as immunotherapy: progress and remaining challenges. <i>OncoTargets and Therapy</i> , 2016, 9, 2627.	1.0	75
17	Viruses as nanomedicine for cancer. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4835-4847.	3.3	24
18	Mechanism of Action and Applications of Interleukin 24 in Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 869.	1.8	59
19	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7081-7093.	1.0	83

#	ARTICLE	IF	CITATIONS
20	Current Immunotherapeutic Treatments in Colon Cancer. , 2016, , .		2
21	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	1.8	13
22	Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 298-308.	1.8	115
23	Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. Journal of Clinical & Cellular Immunology, 2016, 7, .	1.5	16
24	Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses, 2016, 8, 9.	1.5	79
25	Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Research and Therapy, 2016, 7, 149.	2.4	44
26	Prospects and progress of oncolytic viruses for treating peripheral nerve sheath tumors. Expert Opinion on Orphan Drugs, 2016, 4, 129-138.	0.5	8
27	Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus. Molecular Cancer Therapeutics, 2016, 15, 767-773.	1.9	48
28	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
29	Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses. ILAR Journal, 2016, 57, 63-72.	1.8	10
30	Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro. Journal of Translational Medicine, 2016, 14, 241.	1.8	12
31	Science in Focus "Oncolytic Viruses: New Multifunctional Immunotherapeutics. Clinical Oncology, 2016, 28, 615-618.	0.6	2
32	Oncolytic herpes simplex virus interactions with the host immune system. Current Opinion in Virology, 2016, 21, 26-34.	2.6	44
33	Surgical immune interventions for solid malignancies. American Journal of Surgery, 2016, 212, 682-690.e5.	0.9	9
34	Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAAd-S-pk7, administered by intracerebral injection to Syrian hamsters. Journal of Translational Medicine, 2016, 14, 134.	1.8	12
35	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer Journal (Sudbury, Mass), 2016, 22, 257-266.	1.0	38
36	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
37	Talimogene laherparepvec in advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 781-788.	0.5	0

#	ARTICLE	IF	CITATIONS
38	Genomic determinants of cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 41, 32-38.	2.4	27
39	The oncolytic virus \hat{I}^{PK} has multimodal anti-tumor activity. <i>Pathogens and Disease</i> , 2016, 74, ftw050.	0.8	9
40	Inactivated Tianjin strain, a novel genotype of Sendai virus, induces apoptosis in HeLa, NCI-H446 and Hep3B cells. <i>Oncology Letters</i> , 2016, 12, 49-56.	0.8	5
41	Oncolytic viruses: finally delivering. <i>British Journal of Cancer</i> , 2016, 114, 357-361.	2.9	95
42	Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2918-2927.	2.9	77
43	Experimental therapies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 183-197.	1.0	22
44	Metal-dependent Deacetylases: Cancer and Epigenetic Regulators. <i>ACS Chemical Biology</i> , 2016, 11, 706-716.	1.6	31
45	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	0.6	126
46	Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy. <i>Biomaterials</i> , 2016, 89, 56-66.	5.7	83
47	CD8+ T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy. <i>EBioMedicine</i> , 2016, 5, 59-67.	2.7	29
48	CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. <i>Oncotarget</i> , 2016, 5, e1091554.	2.1	83
49	Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. <i>Gene Therapy</i> , 2016, 23, 18-25.	2.3	25
50	Potential and clinical translation of oncolytic measles viruses. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 353-363.	1.4	41
51	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma—Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 50.	2.0	10
52	Mathematical and Computational Modeling for Tumor Virotherapy with Mediated Immunity. <i>Bulletin of Mathematical Biology</i> , 2017, 79, 1736-1758.	0.9	15
53	Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma. <i>Annals of Pharmacotherapy</i> , 2017, 51, 675-681.	0.9	29
54	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. <i>Cancer Treatment Reviews</i> , 2017, 60, 32-43.	3.4	116
55	Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission. <i>Endocrine-Related Cancer</i> , 2017, 24, T311-T329.	1.6	23

#	ARTICLE	IF	CITATIONS
56	A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response. <i>Biomaterials</i> , 2017, 147, 26-38.	5.7	43
57	Cancer Immunotherapies: Are They as Effective in the Elderly?. <i>Drugs and Aging</i> , 2017, 34, 567-581.	1.3	31
58	Infection: a Cause of and Cure for Cancer. <i>Current Pharmacology Reports</i> , 2017, 3, 315-320.	1.5	13
59	Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 681-689.	2.5	191
60	Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. <i>Gene Therapy</i> , 2017, 24, 21-30.	2.3	61
61	Towards targeted cancer therapy: Aptamer or oncolytic virus?. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 8-19.	1.9	23
62	Oncolytic Viruses in Cancer Treatment. <i>JAMA Oncology</i> , 2017, 3, 841.	3.4	426
64	Considerations for the Development of Innovative Therapies Against Aggressive Neuroblastoma: Immunotherapy and Twist1 Targeting. , 2017, , .		0
65	Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity. <i>Viruses</i> , 2017, 9, 382.	1.5	36
66	Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. <i>Frontiers in Oncology</i> , 2017, 7, 202.	1.3	107
67	The Role of the Innate Immune System in Oncolytic Virotherapy. <i>Computational and Mathematical Methods in Medicine</i> , 2017, 2017, 1-17.	0.7	24
68	Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 31-38.	6.0	9
69	Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. <i>PLoS ONE</i> , 2017, 12, e0184347.	1.1	44
70	Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. <i>Cancer Cell</i> , 2018, 33, 599-605.	7.7	178
71	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
72	Oncolytic Viruses: T-VEC and Others. , 2018, , 387-403.		1
73	The Basics of Cancer Immunotherapy. , 2018, , .		5
74	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3

#	ARTICLE	IF	CITATIONS
75	Mesenchymal stem cells: A new platform for targeting suicide genes in cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 3831-3845.	2.0	63
76	Biologic and Immunotherapy Developments in Advanced Hepatocellular Carcinoma. , 2018, , .		0
77	Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens. <i>Cells</i> , 2018, 7, 228.	1.8	8
78	Molecular survey on Merkel cell polyomavirus in patients with colorectal cancer. <i>Medical Journal of Indonesia</i> , 2018, 27, 229-36.	0.2	4
79	Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 1612-1623.	3.2	120
80	Poly-Gamma-Glutamic Acid (γ -PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies. <i>Molecules</i> , 2018, 23, 2565.	1.7	31
81	Selecting immuno-oncologyâ€‘based drug combinations â€‘ what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 971-985.	1.3	5
82	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
83	Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses. <i>Porto Biomedical Journal</i> , 2018, 3, e7.	0.4	8
84	Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 30-42.	2.0	32
85	Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	57
86	Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2188.	1.8	23
87	The Emerging Therapeutic Landscape of Advanced Melanoma. <i>Current Pharmaceutical Design</i> , 2018, 24, 549-558.	0.9	16
88	Advances in oncolytic adenovirus therapy for pancreatic cancer. <i>Cancer Letters</i> , 2018, 434, 56-69.	3.2	33
89	Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. <i>Immunotherapy</i> , 2018, 10, 779-786.	1.0	58
90	Virus-Based Therapeutic Approaches. , 2018, , 243-276.		3
91	A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection. <i>Molecular Therapy - Oncolytics</i> , 2018, 9, 13-21.	2.0	28
92	Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens. <i>Current Cancer Drug Targets</i> , 2018, 18, 162-170.	0.8	16

#	ARTICLE	IF	CITATIONS
93	Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials. <i>Scientific Reports</i> , 2018, 8, 11800.	1.6	23
94	Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro. <i>Journal of Cancer</i> , 2018, 9, 1033-1049.	1.2	16
95	Cancer immunotherapy for metastasis: past, present and future. <i>Briefings in Functional Genomics</i> , 2019, 18, 140-146.	1.3	10
96	Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. <i>Frontiers in Immunology</i> , 2019, 10, 1848.	2.2	56
97	Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. , 2019, 7, 174.		13
98	Optimizing oncolytic virotherapy in cancer treatment. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 689-706.	21.5	325
99	Backward Hopf bifurcation in a mathematical model for oncolytic virotherapy with the infection delay and innate immune effects. <i>Journal of Biological Dynamics</i> , 2019, 13, 733-748.	0.8	10
100	Syncytia Formation in Oncolytic Virotherapy. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 131-139.	2.0	25
101	Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-17.	0.7	8
102	From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 396.	3.5	265
104	H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. <i>Viruses</i> , 2019, 11, 562.	1.5	40
105	Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. <i>World Neurosurgery</i> , 2019, 129, 90-100.	0.7	52
106	Local Therapies. , 2019, , 159-172.		0
107	An efficient or methodical review of immunotherapy against breast cancer. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22339.	1.4	14
108	A mathematical model of viral oncology as an immuno-oncology instigator. <i>Mathematical Medicine and Biology</i> , 2020, 37, 117-151.	0.8	9
109	Spatial Model for Oncolytic Virotherapy with Lytic Cycle Delay. <i>Bulletin of Mathematical Biology</i> , 2019, 81, 2396-2427.	0.9	9
110	Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 223-232.	2.0	22
111	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52

#	ARTICLE	IF	CITATIONS
112	Updates to the antitumor mechanism of oncolytic virus. <i>Thoracic Cancer</i> , 2019, 10, 1031-1035.	0.8	48
113	Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 537-546.	0.6	61
114	Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 443-455.	1.4	26
115	Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. <i>International Immunopharmacology</i> , 2019, 70, 498-503.	1.7	21
116	Anticancer Activities of Natural and Synthetic Peptides. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1117, 131-147.	0.8	59
117	Antimicrobial Peptides. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	26
118	Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. <i>Journal of Translational Medicine</i> , 2019, 17, 100.	1.8	28
119	Orthotopic hepatocellular carcinoma: molecular imaging-monitored intratumoral hyperthermia-enhanced direct oncolytic virotherapy. <i>International Journal of Hyperthermia</i> , 2019, 36, 343-349.	1.1	15
120	Virus-Based Immunotherapy of Glioblastoma. <i>Cancers</i> , 2019, 11, 186.	1.7	107
121	What is the future of cancer care? A technology foresight assessment of experts'™ expectations. <i>Economics of Innovation and New Technology</i> , 2019, 28, 635-652.	2.1	11
122	Synergistic Effects of Bortezomib-OV Therapy and Anti-Invasive Strategies in Glioblastoma: A Mathematical Model. <i>Cancers</i> , 2019, 11, 215.	1.7	15
123	Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus. <i>Oncology Letters</i> , 2019, 18, 5534-5542.	0.8	13
124	The alternative cap-binding complex is required for antiviral defense in vivo. <i>PLoS Pathogens</i> , 2019, 15, e1008155.	2.1	19
125	Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization. <i>PLoS Computational Biology</i> , 2019, 15, e1007495.	1.5	44
126	Tangential Flow Filtration for the Concentration of Oncolytic Measles Virus: The Influence of Filter Properties and the Cell Culture Medium. <i>Membranes</i> , 2019, 9, 160.	1.4	12
127	Zika Virus as Oncolytic Therapy for Brain Cancer: Myth or Reality?. <i>Frontiers in Microbiology</i> , 2019, 10, 2715.	1.5	12
128	Bibliometric analysis of oncolytic virus research, 2000 to 2018. <i>Medicine (United States)</i> , 2019, 98, e16817.	0.4	31
129	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 126-137.	3.3	12

#	ARTICLE	IF	CITATIONS
130	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <i>Neuro-Oncology</i> , 2019, 21, 14-25.	0.6	69
131	Glioblastoma Therapy in the Age of Molecular Medicine. <i>Trends in Cancer</i> , 2019, 5, 46-65.	3.8	68
132	Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer. <i>Journal of Surgical Research</i> , 2020, 245, 127-135.	0.8	11
134	Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. , 2020, 207, 107456.		42
135	Advancing Aptamers as Molecular Probes for Cancer Theranostic Applicationsâ€”The Role of Molecular Dynamics Simulation. <i>Biotechnology Journal</i> , 2020, 15, e1900368.	1.8	22
136	Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. <i>Nanomedicine</i> , 2020, 15, 93-110.	1.7	24
137	Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 102-114.	3.2	7
138	CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 2062.	2.2	45
139	Protein drug-drug interactions for therapeutic modalities. , 2020, , 387-416.		1
140	Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2020, 19, 240-252.	2.0	1
141	Effects of oncolytic viruses and viral vectors on immunity in glioblastoma. <i>Gene Therapy</i> , 2022, 29, 115-126.	2.3	20
142	The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing. <i>Cell Death and Disease</i> , 2020, 11, 1022.	2.7	18
143	The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 115-123.	3.2	5
144	Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 965-983.	1.1	8
145	The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 555-565.	0.9	10
146	Bio-Inorganic Hybrid Nongenetically Modified Viruses as an Immune Agonist for Systemic Elimination of Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 53691-53704.	4.0	2
147	Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 221.	2.4	26
148	Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8310.	1.8	26

#	ARTICLE	IF	CITATIONS
149	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 659-684.	1.9	15
150	Optimising Hydrogel Release Profiles for Viro-Immunotherapy Using Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Immature Dendritic Cells. Applied Sciences (Switzerland), 2020, 10, 2872.	1.3	20
151	Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy?. Molecular Therapy - Oncolytics, 2020, 17, 1-8.	2.0	11
152	Reverse genetic approaches for the development of Zika vaccines and therapeutics. Current Opinion in Virology, 2020, 44, 7-15.	2.6	3
153	Viral Vector-Based Melanoma Gene Therapy. Biomedicines, 2020, 8, 60.	1.4	16
154	Bibliogrpahy. , 2020, , 327-335.		0
155	Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors. Molecular Therapy, 2020, 28, 1276-1286.	3.7	29
156	Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis. Scientific Reports, 2020, 10, 4307.	1.6	19
157	Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neuro-Oncology Practice, 2020, 7, 465-476.	1.0	10
158	Development of oncolytic virotherapy: from genetic modification to combination therapy. Frontiers of Medicine, 2020, 14, 160-184.	1.5	40
159	Electromagnetism and the Microbiome(s). , 2020, , 299-331.		3
160	Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Scientific Reports, 2020, 10, 5095.	1.6	28
161	A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies. Annual Review of Virology, 2020, 7, 537-557.	3.0	20
162	The Double-Edged Sword Role of Viruses in Gastric Cancer. Cancers, 2020, 12, 1680.	1.7	6
163	IFN-I Independent Antiviral Immune Response to Vesicular Stomatitis Virus Challenge in Mouse Brain. Vaccines, 2020, 8, 326.	2.1	8
164	Traveling through phase-parameter portrait. , 2020, , 225-249.		0
165	STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy. International Journal of Molecular Sciences, 2020, 21, 1106.	1.8	47
166	Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Molecular Therapy, 2020, 28, 794-804.	3.7	42

#	ARTICLE	IF	CITATIONS
167	Intratumoural immunotherapies in oncology. <i>European Journal of Cancer</i> , 2020, 127, 1-11.	1.3	12
168	Prospects of biological and synthetic pharmacotherapies for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 305-317.	1.4	16
169	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
170	Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. <i>Journal of Immunology</i> , 2020, 204, 1386-1394.	0.4	37
171	Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. <i>Digestive Diseases and Sciences</i> , 2021, 66, 359-368.	1.1	43
172	Hopf and backward bifurcations induced by immune effectors in a cancer oncolytic virotherapy dynamics. <i>International Journal of Dynamics and Control</i> , 2021, 9, 840-861.	1.5	4
173	The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 391-410.	2.5	20
174	Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma. <i>Molecular Therapy</i> , 2021, 29, 744-761.	3.7	24
175	A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 71-81.	2.0	11
176	A snapshot of the PD-1/PD-L1 pathway. <i>Journal of Cancer</i> , 2021, 12, 2735-2746.	1.2	105
177	Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200669.	1.5	12
178	The inflammation during colorectal cancer: A friend or a foe?. , 2021, , 103-129.		1
179	Self-assembled Viral Nanoparticles as Targeted Anticancer Vehicles. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 25-38.	1.4	14
180	The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. <i>Neurosurgical Focus</i> , 2021, 50, E8.	1.0	16
181	Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. <i>Cancers</i> , 2021, 13, 588.	1.7	18
182	Targeting macrophages in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 127.	7.1	300
183	Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. , 2021, 9, e001930.		21
184	A bibliometric review of oncolytic virus research as a novel approach for cancer therapy. <i>Virology Journal</i> , 2021, 18, 98.	1.4	10

#	ARTICLE	IF	CITATIONS
185	Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 971-980.	4.3	17
186	An Oncolytic Virus Expressing IL15/IL15R α Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. <i>Cancer Research</i> , 2021, 81, 3635-3648.	0.4	89
187	Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma. <i>Frontiers in Oncology</i> , 2021, 11, 678226.	1.3	6
188	Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 513-524.	1.1	6
189	Stem cells for the treatment of glioblastoma: a 20-year perspective. <i>CNS Oncology</i> , 2021, 10, CNS73.	1.2	14
190	Oncolytic viruses as a promising therapeutic strategy for hematological malignancies. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111573.	2.5	12
191	Antifibrotic Therapy Augments the Antitumor Effects of Vesicular Stomatitis Virus Via Reprogramming Tumor Microenvironment. <i>Human Gene Therapy</i> , 2022, 33, 237-249.	1.4	2
192	Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma. <i>Viruses</i> , 2021, 13, 1677.	1.5	5
193	The Multifaceted Role of Macrophages in Oncolytic Virotherapy. <i>Viruses</i> , 2021, 13, 1570.	1.5	11
194	Oncolytic virus therapy in cancer: A current review. <i>World Journal of Virology</i> , 2021, 10, 229-255.	1.3	65
195	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
196	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. <i>Annals of Oncology</i> , 2021, 32, 1537-1551.	0.6	36
197	Bacteria-based immune therapies for cancer treatment. <i>Seminars in Cancer Biology</i> , 2022, 86, 1163-1178.	4.3	10
198	The Viral Janus: Viruses as Aetiological Agents and Treatment Options in Colorectal Cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 601573.	1.8	8
199	Introduction to RNA Vaccines. <i>Methods in Molecular Biology</i> , 2017, 1499, 1-11.	0.4	37
200	Cancer Nanomedicine: Special Focus on Cancer Immunotherapy. , 2021, , 465-508.		2
201	Therapeutic Cancer Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 139-167.	0.8	12
202	Gene Delivery in Neuro-Oncology. <i>Current Oncology Reports</i> , 2017, 19, 69.	1.8	18

#	ARTICLE	IF	CITATIONS
203	Î”PK oncolytic activity includes modulation of the tumour cell milieu. Journal of General Virology, 2016, 97, 496-508.	1.3	29
204	CD55 is a key complement regulatory protein that counteracts complement-mediated inactivation of Newcastle Disease Virus. Journal of General Virology, 2016, 97, 1765-1770.	1.3	11
205	Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity. Journal of Clinical Investigation, 2018, 129, 518-530.	3.9	32
206	Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. Journal of Clinical Investigation, 2019, 129, 2279-2292.	3.9	37
207	Oncolytic viruses: overcoming translational challenges. Journal of Clinical Investigation, 2019, 129, 1407-1418.	3.9	70
208	Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. Journal of Clinical Investigation, 2015, 125, 4269-4280.	3.9	57
209	Viruses of protozoan parasites and viral therapy: Is the time now right?. Virology Journal, 2020, 17, 142.	1.4	22
210	Exploring the antitumor effect of virus in malignant glioma. Drugs of the Future, 2015, 40, 0739.	0.0	25
211	Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. Journal of Liver Cancer, 2019, 19, 1-11.	0.3	4
212	Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. Oncotarget, 2017, 8, 89391-89405.	0.8	25
213	The oncolytic virus<i>dl</i>922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget, 2016, 7, 1500-1515.	0.8	58
214	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Annals of Translational Medicine, 2016, 4, 165-165.	0.7	19
215	Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status. Current Pharmaceutical Design, 2020, 25, 4251-4263.	0.9	7
216	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 748.	1.4	16
217	Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis <i>in vitro</i> and <i>in vivo</i>. Oncology Letters, 2020, 21, 99.	0.8	6
218	Advanced Therapy Medicines Based on Oncolytic Viruses (Part I: Development and Authorisation of) Tj ETQq1 1 0.784314 rgBT /Overl... 2021, 11, 148-159.	0.1	1
219	New Approaches to Glioblastoma. Annual Review of Medicine, 2022, 73, 279-292.	5.0	14
220	Oncoviruses: An overview of oncogenic and oncolytic viruses. Oncobiology and Targets, 2015, 2, 4.	0.2	0

#	ARTICLE	IF	CITATIONS
221	Clinical Trials with Oncolytic Viruses: Current and Future Prospects. Journal of Contemporary Dental Practice, 2015, 16, 0-0.	0.2	1
222	Combining Bifurcation Analysis and Population Heterogeneity to Ask Meaningful Questions. STEAM-H: Science, Technology, Engineering, Agriculture, Mathematics & Health, 2019, , 89-110.	0.0	0
223	Oncolytic Viruses As Immunotherapeutic Agents for the Treatment of Malignant Tumors. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 108-117.	0.2	0
224	Immunotherapy and Gliomas. , 2020, , 251-265.		0
225	Hepatobiliary Tumors: Immunopathology and Immunotherapy. , 2020, , 241-259.		0
226	Oncolytic Virus Affects the RAS Pathway in Cancer: RNA Sequence Analysis. Journal of Oncology Research and Therapy, 2021, 6, .	0.0	0
227	MECHANISMS AND CLINICAL EFFECTS OF DRUGS BASED ON ONCOLYTIC ADENOVIRUSES, HERPES VIRUSES, REOVIRUSES AND MEASLES VIRUS. Juvenis Scientia, 2020, 6, 6-17.	0.1	0
228	Immunotherapy in Nonmelanoma Skin Cancers. , 2020, , 291-304.		0
229	In Vitro Anti-cancer Activity of Adipose-Derived Mesenchymal Stem Cells Increased after Infection with Oncolytic Reovirus. Advanced Pharmaceutical Bulletin, 2021, 11, 361-370.	0.6	3
230	Immunotherapy in anaplastic thyroid cancer. American Journal of Translational Research (discontinued), 2020, 12, 974-988.	0.0	10
231	Evaluation of Apoptosis Induction by Newcastle Disease Virus LaSota Strain in Human Breast Carcinoma Cells. Archives of Razi Institute, 2020, 75, 367-376.	0.4	1
232	Modeling the virus-induced tumor-specific immune response with delay in tumor virotherapy. Communications in Nonlinear Science and Numerical Simulation, 2022, 108, 106196.	1.7	6
233	Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses. World Journal of Surgical Oncology, 2022, 20, 16.	0.8	12
234	In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1073-1085.	1.2	4
235	Immunotherapy for cancer treatment. , 2022, , 269-286.		0
236	Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade. Molecular Therapy - Oncolytics, 2022, 24, 299-318.	2.0	9
237	Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?. Frontiers in Oncology, 2021, 11, 761015.	1.3	15
238	Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment. Drug Discovery Today, 2022, 27, 1689-1697.	3.2	5

#	ARTICLE	IF	CITATIONS
239	Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3 β Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity. , 2022, 10, e003950.		11
241	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. Advanced Science, 2022, 9, e2200027.	5.6	26
242	Immunotherapy of glioblastoma: Recent advances and future prospects. Human Vaccines and Immunotherapeutics, 2022, 18, 1-16.	1.4	29
243	An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. , 2021, 9, e002843.		29
244	Clinical Trials of Oncolytic Viruses in Breast Cancer. Frontiers in Oncology, 2021, 11, 803050.	1.3	13
245	Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance. International Journal of Molecular Sciences, 2021, 22, 13521.	1.8	5
246	Oncolytic viruses: A novel treatment strategy for breast cancer. Genes and Diseases, 2021, , .	1.5	4
248	Oncolytic viruses and pancreatic cancer. Cancer Treatment and Research Communications, 2022, 31, 100563.	0.7	5
249	Gastric Cancer and Viruses: A Fine Line between Friend or Foe. Vaccines, 2022, 10, 600.	2.1	3
250	Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. Frontiers in Immunology, 2022, 13, 866892.	2.2	5
251	Heterogeneity of the tumor immune microenvironment and its clinical relevance. Experimental Hematology and Oncology, 2022, 11, 24.	2.0	40
253	Differential In Vitro Growth and Cell Killing of Cancer versus Benign Prostate Cells by Oncolytic Parainfluenza Virus. Pathogens, 2022, 11, 493.	1.2	7
254	Virus-Based Immuno-Oncology Models. Biomedicines, 2022, 10, 1441.	1.4	4
255	Nano-Biomaterials for Immunotherapy Applications. , 2022, , 30-48.		0
256	Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47 Δ combination therapy against glioblastoma. Molecular Therapy - Oncolytics, 2022, 26, 265-274.	2.0	30
257	Treat and repeat: oncolytic virus therapy for brain cancer. Nature Medicine, 2022, 28, 1540-1542.	15.2	7
258	CD24 Expression Dampens the Basal Antiviral State in Human Neuroblastoma Cells and Enhances Permissivity to Zika Virus Infection. Viruses, 2022, 14, 1735.	1.5	6
259	Interdisciplinary Approach in Gastrointestinal Cancers. , 2022, , 1-16.		0

#	ARTICLE	IF	CITATIONS
260	Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in vitro and in vivo. <i>Cancer Management and Research</i> , 0, Volume 14, 2749-2761.	0.9	4
261	Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
262	Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. <i>Hepatology</i> , 2023, 77, 1943-1957.	3.6	5
263	Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	7
264	Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
265	Evaluation of MMR live attenuated vaccine oncolytic potential using Ehrlich ascites carcinoma in a murine model. , 2023, 40, .		3
266	Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 3262.	1.4	2
267	Modeling and Analyzing Homogeneous Tumor Growth under Virotherapy. <i>Mathematics</i> , 2023, 11, 360.	1.1	0
268	Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35. <i>Anticancer Research</i> , 2023, 43, 537-546.	0.5	2
269	Modeling of intracranial tumor treating fields for the treatment of complex high-grade gliomas. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
270	Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases. <i>Cancer Gene Therapy</i> , 0, , .	2.2	1
271	Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model. <i>Cells</i> , 2023, 12, 507.	1.8	2
272	Stem Cells and Tumor-Killing Virus to Target Brain Tumor: In Pursuit to Bring a Potential Delivery Vehicle for the Central Nervous System Tumors. <i>Current Drug Delivery</i> , 2023, 20, .	0.8	0
273	Myeloid cells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
274	Drug repurposing for viral cancers: A paradigm of machine learning, deep learning, and virtual screening-based approaches. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	13
275	Intravesical oncolytic virotherapy and immunotherapy for <scp>non-muscle</scp>-invasive bladder cancer mouse model. <i>BJU International</i> , 2023, 132, 298-306.	1.3	0
276	Infectious Recombinant Senecavirus A Expressing p16INK4A Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6139.	1.8	1
277	Mesenchymal stem cells: a trojan horse to treat glioblastoma. <i>Investigational New Drugs</i> , 2023, 41, 240-250.	1.2	2

#	ARTICLE	IF	CITATIONS
278	Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. <i>Translational Medicine Communications</i> , 2023, 8, .	0.5	3
279	Comparison of Regulations for the Development of Oncolytic Virus Therapy in the United States, the European Union, and Japan.. , 2016, 4, 1-9.		1
282	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
294	Polymer-mediated nanoformulations: a promising strategy for cancer immunotherapy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2024, 397, 1311-1326.	1.4	0